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Introduction
Laparoscopic splenectomy (LS) is a well-accepted proce-
dure for the treatment of benign diseases, mainly in healthy
patients with a small spleen, as in idiopathic thrombocy-
topenic purpura [1,2]. However, experience with LS for
haematological malignancies is limited, and comparative
studies with open operation are lacking [3,4]. Malignant
haematological diseases have specific clinical features (e.g.
splenomegaly, advanced patient age and more severe clini-
cal disease) which increase the difficulty of the procedure
or may have an impact on the immediate outcome after LS
[5,6]. The aim of this study was to analyse the immediate
outcome of LS, comparing benign with malignant diag-
noses in a prospective series of 137 procedures.
Patients and methods
Between February 1993 and April 2000, 137 patients with
a wide range of splenic disorders underwent LS (Table 1).
Of these, 132 were operated using techniques previously
described in detail [7], but in 5 patients with an enlarged
spleen LS was performed with hand-assisted techniques
(Hand Port, Smith and Nephew Endoscopy, Andover, MA,
USA). Patients were classified as benign (group I) or malig-
nant (group II) according to the haematological diagnosis.
Clinical data, technical details and immediate outcome
were recorded prospectively (Table 2). Student’s t test and
2 tests were used for relevant comparisons between series.
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Background 
Laparoscopic splenectomy (LS) is widely accepted for
treatment of benign diseases, but there are few reports of
its use in cases of haematological malignancy. In addition,
comparative studies with open operation are lacking.
Malignant haematological diseases have specific clinical fea-
tures – notably splenomegaly and impaired general health
– which can impact on the immediate outcome after LS.
The immediate outcome of LS comparing benign with
malignant diagnoses has been analysed in a prospective
series of 137 operations.
Patients and methods
Between February 1993 and April 2000, 137 patients with
a wide range of splenic disorders received LS. Clinical data
and immediate outcome were prospectively recorded, and
age, diagnosis, operation time, perioperative transfusion
requirement, spleen weight, conversion rate, accessory
incision, hospital stay and complications were analysed.
Results 
The series included 100 benign cases and 37 suspected
malignancies . In patients with malignant diseases the mean
age was greater (37 years [3–85] vs 60 years [27–82],
p,0.01), LS took longer (138 min [60–400] vs 161 min
[75–300], p,0.05) and an accessory incision for spleen
retrieval was required more frequently (18% vs 93%,
p,0.01) because the spleen was larger (279 g [60–1640] vs
1210 g [248–3100], p,0.01). However, the rate of conver-
sion to open operation (5% vs 14%), postoperative mor-
bidity rate (13% vs 22%) and transfusion requirement (15%
vs 26%) did not differ between benign and malignant cases.
Hospital stay was longer in malignant cases (3.7 days
[2–14] vs 5 days [2–14], p,0.05).
Conclusion 
LS is a safe procedure in patients with malignant disease
requiring splenectomy in spite of the longer operative time
and the higher conversion rate.
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Results
In the malignant group, the most frequent diagnoses were
non-Hodgkin’s lymphoma (18/37, 46%) and myelofibrosis
(4/37, 11%) (Table 1). In 15 patients, the LS was per-
formed for diagnostic purposes and in 13 for hypersplenism.
In two cases (myelofibrosis and LMC), LS was performed
before bone marrow transplantation. There were two
patients with acquired immune deficiency syndrome
(AIDS), in whom malignancy was suspected due to
splenomegaly, fever and hypersplenism, although it was not
confirmed by histological analysis. The detailed preopera-
tive and immediate results of each group are described in
Tables 2 and 3. Patients in group II were significantly older
and LS took significantly longer; most of them (93%)
required an accessory incision at the end of the procedure
to extract the intact spleen (at the request of the patholo-
gist). These spleens were also heavier, but in spite of a slight
increase in transfusion and morbidity rate, the difference
was not statistically significant. However, postoperative
stay was longer in the malignant group. There were no
operative deaths in this series.
Discussion
The minimally invasive technique has been progressively
accepted among surgeons as an advantageous and safe
approach for splenectomy [1,8]. However, it is a complex
laparoscopic procedure and most series include patients
with benign diseases and small spleens. LS for malignant
disease is a greater challenge for the surgeon because of the
size of the spleen and the general condition of the patient
[3,4,8]. In the pre-laparoscopy era, substantial morbidity
and even the occasional death followed open splenectomy
for malignancy [6]. However, few authors have analysed the
results of the application of LS in this group of patients. The
main results of this study show that LS is feasible and safe in
cases of malignancy, and it appears to present the same
advantages as in benign cases (despite the lack of a prospec-
tive randomised comparison with open splenectomy).
At present, splenectomy for malignancy is mainly lim-
ited to treating symptomatic hypersplenism or debulking
patients with established disease, or for diagnosis in sus-
pected cases. Surgical staging of Hodgkin’s disease has been
replaced by noninvasive methods, and splenectomy is
reserved for more severe haematological diagnoses. In our
study we included two patients with an infrequent clinical
problem: splenomegaly and hypersplenism in AIDS
patients in whom a lymphoma was suspected. Like other
authors [3,4], we found that patients with malignant
haematological diseases were older and that operative time
was longer than in benign cases, but the conversion rate
remained low in spite of the relatively large size of the
spleen. The three series published to date (Table 3)
analysing LS for malignancy show similar operative times,
morbidity and transfusion rates. However, Berman and col-
leagues [3] reported a higher conversion rate (41%), in
spite of the use of a hand-assisted technique in some cases. 
Although there are no prospective randomised trials,
the analysis of comparative trials of laparoscopic versus
open splenectomy or the comparison of results of LS for
malignant cases with recent published series of open
splenectomy are in favour of LS; transfusion rates and
major morbidity are reduced. In a recent study, Nelson and
co-workers [9] showed a morbidity and mortality rate of
41% and 8% and a mean hospital stay of 13 days in a series
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Autoimmune thrombocytopenic purpura (ITP) 59
HIV-related thrombocytopenia 7
















Hairy cell lymphoma 5
Myelofibrosis 4
Chronic lymphocytic leukaemia 3
Chronic myeloid leukaemia 1
Waldenström’s macroglobulinaemia 1
HIV, splenomegaly and suspicion of malignancy 2
Metastatic histiocytoma 1
of 39 patients. Most of these splenectomies were considered
‘high risk’ because of non Hodgkin’s lymphomas and a
mean spleen weight of 1500 g. In a similar series, LS was
followed by a reduced major morbidity (18–23%), lower
mortality and reduced hospital stay [3,4,10,11]. In our
series, five of eight complications were not technically
related, and only one patient had pulmonary problems.
Although there were no pancreatic injuries or subphrenic
infections, three patients had to be reoperated for bleeding;
but no clear bleeding source was found. In a recent multi-
variate study analysing factors related to complications dur-
ing LS, we observed that malignancy, spleen weight and age
were independent factors. The learning curve was another
independent factor [12]. Thus patients with malignant dis-
ease are the most difficult cases for LS and need an
experienced team.
From the technical point of view, the most challenging
step is the mobilisation of a large organ inside the abdomi-
nal cavity and its retrieval. The main reason for conver-
sion in our malignant group was spleen size, due to the
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Table 2. Clinical features and immediate outcome after LS according to benign or malignant haematological diagnosis
Group I: benign Group II: malignant
Laparoscopic Converted (5%) Laparoscopic Converted (14%)
n 95 5 32 5
Age (years) 36 (3–68) 48 (16–85) 59 (28–82)* 62 (57–75)
Operation time (min) 138 (60–400) 187 (135–240) 161 (75–300)† 162 (110–210)
Accessory incision 18% 93%*
Size of accessory 
incision 5 (3–12) 11(6–18)*
Transfusion rate 15% 80% 26% 80%
Morbidity rate 13% 20% 22% 40%
Stay (days) 3.7 (2 – 14) 6 (4–7) 5 (2–14)* 6 (4–15)
Reoperation 1 1 2 1
Spleen weight (g) 279 (60–1640) 1095 (175–3400) 1210 (248–3100)* 2856 (1824–3519)
Complications
Lung infection (3) Haemoperitoneum Urinary infection Haemoperitoneum
Subphrenic haematoma Gout Ileus
Abdominal wall haematoma (2) Haemoperitoneum Pleural effusion
Haemoperitoneum (2) Ileus
Fever (2) Sweet’s syndrome
Haemopneumothorax Catheter sepsis
Wound sepsis Pneumonia
*, 0.01 vs benign laparoscopic,
†
,0.05 vs benign laparoscopic.
Table 3. Comparative studies of laparoscopic splenectomy for benign or malignant haematological diseases
Schlachta (1999) Decker (1998)
Benign Malignant p Benign Malignant p
n 50 14 22 13
Age 36±18 54±16 0.002 42±16 60±9 0.002
Conversion 6% 21% 0 23%
Op. time 180±60 239±73 0.01 172±67 235±69 0.01
Morbidity rate 11% 18% 27% 15%
Mortality rate – 9% 0 8%
Stay (days) 3 3 4.5±2.7 5±1.2
Size 11 17 0.001
Weight (g) 160±387 1420±850
Transfusion rate 0 0 0 46% 0.005
impossibility of handling; spleens were significantly larger
in the converted subgroup than in the successful LS sub-
group [7,13]. In recent months new devices for
hand-assisted laparoscopic surgery have become available,
and this technique can be especially useful in cases of LS for
splenomegaly or malignancy [14,15]. Five patients in our
series were operated using these techniques and our prelim-
inary opinion is that this device facilitates the procedure
enormously, especially in the final steps of handling the
organ and stapling the hilum. In these five patients spleen
weights ranged between 720 and 3100 g, and the LS lasted
between 75 and 120 min; there were no complications and
the patients were discharged after 3 days (Tables 4 and 5).
This device can also facilitate the retrieval of large organs.
The ‘hand port’ incision was located in the right hypochon-
drium or epigastrium depending on the size of the spleen,
and the final size was 7 cm. We routinely extract the organ
intact through an accessory incision at the request of the
pathologist and so as to avoid the cumbersome manoeuvre
of introducing a large organ into a bag. We consider that
the final extraction incision – which is always much smaller
than a formal laparotomy – maintains the characteristics of
‘minimal invasion’ and has a minimal impact on immediate
outcome. In this situation, the placement of the incision for
the ‘hand-assisted’ device may facilitate the extraction of
the organ at the end of the procedure. 
An unresolved issue is the role of laparoscopic tech-
niques for the treatment of massive splenomegaly (.3000 g).
Obviously, this procedure depends on the expertise of the
surgeon, the shape of the spleen and the abdominal shape
of the patient.
In conclusion, just as LS is being accepted as the stan-
dard treatment in benign cases, so it will have an important
role in the surgical management of malignant cases. This
subset of patients has unique clinical and anatomic fea-
tures, but improvements in technical devices (such as
hand-assisted surgery) are likely to increase the number of
potential candidates and the safety of the procedure. 
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Table 4. Comparison of immediate results of LS for
splenomegaly (n = 39, spleen weight .700 g) treated by
conventional LS and ‘hand-assisted’ LS (HALS)
Group I: LS Group II: HALS
n 34 5 
Age (years) 58 (19–82) 57 (44–72)
Operative time (min) 172 (95–300) 109 (75–120)
Conversion 20% 0
Transfusion rate 38% 20%
Morbidity rate 29% 0
Stay (days) 5.8 (3–14) 3.6 (2–4)
Reoperation 1/34 (3%) 0
Spleen weight (g) 1425 (700–3400) 1524 (720–3100)
Mortality 0 0
Table 3. cont.
Bremann (1999) Walsh (1999)
Benign Malignant p Malignant (NHL)
n 31 22 9
Age 38 (4–85) 55 (24–70) 0.001 55 (34–68)
Conversion 3% 41% 0.001 0
Op. time 155 (109–265) 203 (150–300) 0.005 185 (115–390)
Morbidity rate 9% 32% 0
Mortality rate 0 3% 0
Stay (days) 2 (1–11) 4 (3–24) 0.001 2.4 (1–6)
Size
Weight (g) 164 930 (190–3500) 0.001 765 (380–1000)
Transfusion rate 10% 18% 10%
NHL = non-Hodgkin’s lymphoma.
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